Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Single Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 After Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers Including Food Effect.

Next Previous
Search
Trial Profile

A Phase I, Single Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 After Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers Including Food Effect.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Verdiperstat (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions

    • Most Recent Events

    • 06 Jun 2018 Population pharmacokinetic model for AZD3241 was developed using data from one phase 1 MAD study in healthy subjects (study 02, D0490C00002, NCT00914303), and one phase 2 safety and tolerability study (study 23,D0490C00023, NCT02388295), results published in the Journal of Clinical Pharmacology
    • 24 Mar 2018 Data from one phase I study (NCT00914303) and one phase II study in Multiple System Atrophy (NCT02388295) trial was used to develop PopPK model, results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 01 Apr 2010 Actual patient number (77) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top